Skip to main content
. 2014 Aug 3;94(1):35–43. doi: 10.1007/s00277-014-2178-x

Table 2.

The median (range) values of chosen parameters of AML patients and healthy volunteers

Parameters No. of patients
New diagnosed patients n = 76 Healthy volunteers n = 40 Patients after an induction treatment
After the treatment n = 71 With CR n = 44 With NR n = 27
TRAIL [pg/ml] 68.54 (19.1–104.8) 79.9* (55.4–108.2) 56.52 (19.3–158.8) 74.2 (35.22–158.8) 50.56*** (19.3–88.28)
BAFF [pg/ml] 3615.1 (983.9–9151.4) 651.4* (362.9–1122.3) 3058.1** (972.3–8923.4) 1885.1 (972.3–7645.4) 5036.4*** (1538.2–8923.4)
APRIL [ng/ml] 5.96 (1.65–43.4) 1.68* (1.0–7.56) 5.56 (1.4–69.9) 3.42 (1.4–19.2) 8.89*** (2.1–69.9)
TNF [pg/ml] 9.06 (3.92–83.4) 5.35 * (3.12–7.4) 8.62** (3.8–69.1) 8.51 (3.8–43.1) 9.13 (3.9–69.1)
IL-6 [pg/ml] 12.12 (1.96–43.4) 1.92* (0.87–2.43)* 8.64** (0.57–155.4) 5.42 (0.57–20.1) 19.4*** (4.57–155.4)

The values are presented as median (range)

AML acute myeloid leukaemia, BAFF B cell-activating factor, APRIL a proliferation-inducing ligand, TRAIL TNF-related apoptosis-inducing ligand, TNF tumour necrosis factor, IL-6 interleukin 6, CR complete remission, NR non-responders

*p < 0.05 between AML patients and healthy volunteers

**p < 0.05 between before and after treatment AML patients

***p < 0.05 between patients with CR and NR